Intensity Therapeutics

Historical price data

Intensity Therapeutics is on a mission to transform solid tumor treatment by combining direct tumor killing with in situ vaccination. Its core achievement is the DfuseRx℠ platform, which enhances drug dispersion and penetration within tumors to induce immunogenic cell death and a systemic T-cell response. The company's strategy centers on advancing its lead asset, INT230-6, through late-stage trials in breast cancer and sarcomas, with the goal of validating its platform and creating a new class of cancer immunotherapy. As a public company, it faces the critical challenge of generating pivotal clinical data to support regulatory approval and commercial adoption.

The DfuseRx℠ platform is a proprietary penetration enhancer technology that enables co-injected therapeutic agents to disperse throughout a tumor and efficiently diffuse into cancer cells, inducing immunogenic cell death and a systemic anti-cancer immune response.

Intensity competes with other intratumoral immunotherapy developers (e.g., OncoSec) and must demonstrate superiority or complementarity to entrenched systemic therapies like checkpoint inhibitors and ADCs. Its key differentiators are the dual cytotoxic/immunogenic mechanism and use of well-understood chemotherapeutic agents.